Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

Inclusion Criteria: * Signed, written informed consent by participant or legal representative prior to any trial-specific screening procedure * Male or female, greater than or equal to (\>=) 18 years of age (or have reached the age of majority according to local laws and regulations) * Measurable disease confirmed by an independent review committee (IRC) in accordance with RECIST version 1.1 * Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1 * A female participant was eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: * Not a woman of childbearing potential OR * A woman of childbearing potential who agrees to use a highly effective contraception * A male participant must agree to use and to have their female partners of childbearing potential to use a highly effective contraception * Histologically or cytologically confirmed advanced (locally advanced or metastatic) NSCLC (all types including squamous and sarcomatoid) * Treatment naïve participant in first-line or pretreated participant with no more than 2 lines of prior therapy * Participants with MET alterations, namely METex14 skipping alterations in plasma and/or tissue as determined by the central laboratory or by an assay with appropriate regulatory status Exclusion Criteria: * Participants with characterized Epidermal Growth Factor Receptor (EGFR) activating mutations that predict sensitivity to anti-EGFR-therapy * Partici…